NZ619606B2 - Pharmaceutical composition comprising amide derivative inhibiting the growth of cancer cells and non-metallic salt lubricant - Google Patents
Pharmaceutical composition comprising amide derivative inhibiting the growth of cancer cells and non-metallic salt lubricant Download PDFInfo
- Publication number
- NZ619606B2 NZ619606B2 NZ619606A NZ61960612A NZ619606B2 NZ 619606 B2 NZ619606 B2 NZ 619606B2 NZ 619606 A NZ619606 A NZ 619606A NZ 61960612 A NZ61960612 A NZ 61960612A NZ 619606 B2 NZ619606 B2 NZ 619606B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- pharmaceutical composition
- metallic salt
- compound
- acid
- formula
- Prior art date
Links
- 239000011780 sodium chloride Substances 0.000 title claims abstract description 66
- 150000003839 salts Chemical class 0.000 title claims abstract description 65
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 63
- 239000000314 lubricant Substances 0.000 title claims abstract description 50
- 201000011510 cancer Diseases 0.000 title abstract description 11
- 150000001408 amides Chemical class 0.000 title abstract description 5
- 230000012010 growth Effects 0.000 title description 9
- 230000002401 inhibitory effect Effects 0.000 title description 6
- 150000001875 compounds Chemical class 0.000 claims abstract description 34
- 239000000203 mixture Substances 0.000 claims description 50
- -1 fatty acid esters Chemical class 0.000 claims description 24
- 239000008187 granular material Substances 0.000 claims description 22
- 239000000758 substrate Substances 0.000 claims description 19
- 239000011248 coating agent Substances 0.000 claims description 17
- 238000000576 coating method Methods 0.000 claims description 17
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 17
- 239000000194 fatty acid Substances 0.000 claims description 17
- VZCYOOQTPOCHFL-OWOJBTEDSA-N (E)-but-2-enedioate;hydron Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 15
- QIQXTHQIDYTFRH-UHFFFAOYSA-N Stearic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 12
- 239000011230 binding agent Substances 0.000 claims description 11
- 239000000654 additive Substances 0.000 claims description 10
- 239000000454 talc Substances 0.000 claims description 9
- 229910052623 talc Inorganic materials 0.000 claims description 9
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 claims description 8
- 239000001530 fumaric acid Substances 0.000 claims description 8
- 239000008172 hydrogenated vegetable oil Substances 0.000 claims description 8
- 229920001223 polyethylene glycol Polymers 0.000 claims description 8
- 239000005720 sucrose Substances 0.000 claims description 8
- 239000003085 diluting agent Substances 0.000 claims description 7
- 229920001903 high density polyethylene Polymers 0.000 claims description 7
- 239000004700 high-density polyethylene Substances 0.000 claims description 7
- 239000008118 PEG 6000 Substances 0.000 claims description 6
- IPCSVZSSVZVIGE-UHFFFAOYSA-N Palmitic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims description 6
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 claims description 6
- 229920002472 Starch Polymers 0.000 claims description 6
- 235000021355 Stearic acid Nutrition 0.000 claims description 6
- 239000007884 disintegrant Substances 0.000 claims description 6
- 238000009472 formulation Methods 0.000 claims description 6
- 229940046813 glyceryl palmitostearate Drugs 0.000 claims description 6
- 239000008107 starch Substances 0.000 claims description 6
- 235000019698 starch Nutrition 0.000 claims description 6
- 239000008117 stearic acid Substances 0.000 claims description 6
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N Glyceryl behenate Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 claims description 5
- FETSQPAGYOVAQU-UHFFFAOYSA-N Glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 claims description 5
- 230000000996 additive Effects 0.000 claims description 5
- 150000004665 fatty acids Chemical class 0.000 claims description 5
- 229940049654 glyceryl behenate Drugs 0.000 claims description 5
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 5
- 239000002480 mineral oil Substances 0.000 claims description 5
- 235000010446 mineral oil Nutrition 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 229920001343 polytetrafluoroethylene Polymers 0.000 claims description 5
- VUKAUDKDFVSVFT-UHFFFAOYSA-N 2-[6-[4,5-bis(2-hydroxypropoxy)-2-(2-hydroxypropoxymethyl)-6-methoxyoxan-3-yl]oxy-4,5-dimethoxy-2-(methoxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)-5-methoxyoxane-3,4-diol Chemical compound COC1C(OC)C(OC2C(C(O)C(OC)C(CO)O2)O)C(COC)OC1OC1C(COCC(C)O)OC(OC)C(OCC(C)O)C1OCC(C)O VUKAUDKDFVSVFT-UHFFFAOYSA-N 0.000 claims description 4
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 4
- XAPRFLSJBSXESP-UHFFFAOYSA-N Oxycinchophen Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=C(O)C=1C1=CC=CC=C1 XAPRFLSJBSXESP-UHFFFAOYSA-N 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 4
- GLDOVTGHNKAZLK-UHFFFAOYSA-N Stearyl alcohol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 4
- 239000004359 castor oil Substances 0.000 claims description 4
- 235000019438 castor oil Nutrition 0.000 claims description 4
- 239000002702 enteric coating Substances 0.000 claims description 4
- 238000009505 enteric coating Methods 0.000 claims description 4
- 229940075507 glyceryl monostearate Drugs 0.000 claims description 4
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 4
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 4
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 claims description 4
- VBICKXHEKHSIBG-UHFFFAOYSA-N rac-1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 4
- 230000002459 sustained Effects 0.000 claims description 4
- 229920002301 Cellulose acetate Polymers 0.000 claims description 3
- 235000021314 Palmitic acid Nutrition 0.000 claims description 3
- XNGIFLGASWRNHJ-UHFFFAOYSA-N Phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 claims description 3
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 claims description 3
- DCXXMTOCNZCJGO-UHFFFAOYSA-N Stearin Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 claims description 3
- DUXYWXYOBMKGIN-UHFFFAOYSA-N Trimyristin Chemical compound CCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCC DUXYWXYOBMKGIN-UHFFFAOYSA-N 0.000 claims description 3
- 150000002191 fatty alcohols Chemical class 0.000 claims description 3
- 239000003921 oil Substances 0.000 claims description 3
- 235000019198 oils Nutrition 0.000 claims description 3
- 239000004810 polytetrafluoroethylene Substances 0.000 claims description 3
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 3
- 239000001856 Ethyl cellulose Substances 0.000 claims description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 2
- 229920001249 ethyl cellulose Polymers 0.000 claims description 2
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 2
- 229920000578 graft polymer Polymers 0.000 claims description 2
- 229920002689 polyvinyl acetate Polymers 0.000 claims description 2
- 239000011118 polyvinyl acetate Substances 0.000 claims description 2
- 229920002554 vinyl polymer Polymers 0.000 claims description 2
- 229920002126 Acrylic acid copolymer Polymers 0.000 claims 1
- 230000000087 stabilizing Effects 0.000 claims 1
- LPFWVDIFUFFKJU-UHFFFAOYSA-N 1-[4-[4-(3,4-dichloro-2-fluoroanilino)-7-methoxyquinazolin-6-yl]oxypiperidin-1-yl]prop-2-en-1-one Chemical compound C=12C=C(OC3CCN(CC3)C(=O)C=C)C(OC)=CC2=NC=NC=1NC1=CC=C(Cl)C(Cl)=C1F LPFWVDIFUFFKJU-UHFFFAOYSA-N 0.000 abstract description 14
- 239000012535 impurity Substances 0.000 abstract description 7
- 230000010261 cell growth Effects 0.000 abstract 2
- 239000000539 dimer Substances 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 239000003966 growth inhibitor Substances 0.000 abstract 2
- 229950009876 Poziotinib Drugs 0.000 abstract 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinylpyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 20
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 16
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 16
- 239000000594 mannitol Substances 0.000 description 16
- 235000010355 mannitol Nutrition 0.000 description 16
- 102100010782 EGFR Human genes 0.000 description 15
- 101700039191 EGFR Proteins 0.000 description 15
- FKLJPTJMIBLJAV-UHFFFAOYSA-N 5-(7-(4-(4,5-DIHYDRO-2-OXAZOLYL)PHENOXY)HEPTYL)-3-METHYL ISOXAZOLE Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 description 12
- 230000000052 comparative effect Effects 0.000 description 11
- 229960000913 Crospovidone Drugs 0.000 description 10
- 229940069328 Povidone Drugs 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 10
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 10
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 10
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 10
- 239000003826 tablet Substances 0.000 description 10
- 210000004027 cells Anatomy 0.000 description 9
- 229940079593 drugs Drugs 0.000 description 9
- 229940033134 Talc Drugs 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 238000005755 formation reaction Methods 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 239000008213 purified water Substances 0.000 description 6
- 238000003860 storage Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 229940032147 Starch Drugs 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 235000014755 Eruca sativa Nutrition 0.000 description 4
- 244000024675 Eruca sativa Species 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 231100000486 side effect Toxicity 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 101710042656 BQ2027_MB1231C Proteins 0.000 description 3
- 229940078456 CALCIUM STEARATE Drugs 0.000 description 3
- 206010059866 Drug resistance Diseases 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical class CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 229960000070 antineoplastic Monoclonal antibodies Drugs 0.000 description 3
- 239000008116 calcium stearate Substances 0.000 description 3
- 235000013539 calcium stearate Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical class OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Chemical class OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 229960000060 monoclonal antibodies Drugs 0.000 description 3
- 102000005614 monoclonal antibodies Human genes 0.000 description 3
- 108010045030 monoclonal antibodies Proteins 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N oxalic acid Chemical class OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-N propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 210000004881 tumor cells Anatomy 0.000 description 3
- 238000004450 types of analysis Methods 0.000 description 3
- 229960001456 Adenosine Triphosphate Drugs 0.000 description 2
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Chemical class OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L Calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 2
- 229960001433 Erlotinib Drugs 0.000 description 2
- AAKJLRGGTJKAMG-UHFFFAOYSA-N Erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 2
- XGALLCVXEZPNRQ-UHFFFAOYSA-N Gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Chemical class OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 2
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 2
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 2
- BCFGMOOMADDAQU-UHFFFAOYSA-N Lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N Perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N Salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Chemical class OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical class OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 230000000903 blocking Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000007857 degradation product Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N fumaric acid Chemical class OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 229960002584 gefitinib Drugs 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N malonic acid Chemical class OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 230000002829 reduced Effects 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- 235000015424 sodium Nutrition 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000005550 wet granulation Methods 0.000 description 2
- DMBUODUULYCPAK-UHFFFAOYSA-N 1,3-bis(docosanoyloxy)propan-2-yl docosanoate Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCCCCCC DMBUODUULYCPAK-UHFFFAOYSA-N 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N 2-methyl-2-propenoic acid methyl ester Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 229960005261 Aspartic Acid Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N Benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Chemical class 0.000 description 1
- SXDBWCPKPHAZSM-UHFFFAOYSA-N Bromate Chemical compound OBr(=O)=O SXDBWCPKPHAZSM-UHFFFAOYSA-N 0.000 description 1
- WAGYKROGRKYGMW-UHFFFAOYSA-L C(CCCCCCCCCCCCCCCCCCCCC)(=O)OCC(O)CO.C(CCCCCCCCCCCCCCCCC)(=O)[O-].[Zn+2].C(CCCCCCCCCCCCCCCCC)(=O)[O-] Chemical compound C(CCCCCCCCCCCCCCCCCCCCC)(=O)OCC(O)CO.C(CCCCCCCCCCCCCCCCC)(=O)[O-].[Zn+2].C(CCCCCCCCCCCCCCCCC)(=O)[O-] WAGYKROGRKYGMW-UHFFFAOYSA-L 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N DL-tyrosine Chemical compound OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 229920003134 Eudragit® polymer Polymers 0.000 description 1
- 229960002598 Fumaric acid Drugs 0.000 description 1
- 229960002989 Glutamic Acid Drugs 0.000 description 1
- 206010065430 HER-2 positive breast cancer Diseases 0.000 description 1
- 229940084651 Iressa Drugs 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-Methionine Natural products CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 229960000448 Lactic acid Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N Lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N Malic acid Chemical class OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical class OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 1
- 206010027476 Metastasis Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- GHBFNMLVSPCDGN-UHFFFAOYSA-N Monoctanoin Chemical compound CCCCCCCC(=O)OCC(O)CO GHBFNMLVSPCDGN-UHFFFAOYSA-N 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N Pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 108091000081 Phosphotransferases Proteins 0.000 description 1
- 229940023488 Pill Drugs 0.000 description 1
- 102000001253 Protein Kinases Human genes 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 210000003491 Skin Anatomy 0.000 description 1
- 229960004274 Stearic acid Drugs 0.000 description 1
- 229940120982 Tarceva Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H Tricalcium phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229940094060 Tykerb Drugs 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000000259 anti-tumor Effects 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001413 cellular Effects 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 230000004059 degradation Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000032798 delamination Effects 0.000 description 1
- 230000003111 delayed Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229910001651 emery Inorganic materials 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002708 enhancing Effects 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000000174 gluconic acid Chemical class 0.000 description 1
- 229950006191 gluconic acid Drugs 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- 230000002209 hydrophobic Effects 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003834 intracellular Effects 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical class CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Chemical class 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940099563 lactobionic acid Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 229960004891 lapatinib Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011976 maleic acid Chemical class 0.000 description 1
- 239000001630 malic acid Chemical class 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated Effects 0.000 description 1
- 239000007769 metal material Substances 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- KREXGRSOTUKPLX-UHFFFAOYSA-N octadecanoic acid;zinc Chemical compound [Zn].CCCCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O KREXGRSOTUKPLX-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 1
- 229910052712 strontium Inorganic materials 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000001384 succinic acid Chemical class 0.000 description 1
- 235000011044 succinic acid Nutrition 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000011975 tartaric acid Chemical class 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
- A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
Disclosed herein is a pharmaceutical composition comprising an amide derivative of the compound of formula I, known as poziotinib (1-[4-[4-(3,4-dichloro-2-fluoroanilino)-7-methoxyquinazolin-6-yl]oxypiperidin-1-yl]prop-2-en-1-one) or a pharmaceutically acceptable salt thereof and a non-metallic salt lubricant. The presence of the non-metallic salt lubricant prevents the formuation of the dimer impurity which reduces the activity of the compound of formula I in the treatment of cancer as a cell-growth inhibitor. lubricant. The presence of the non-metallic salt lubricant prevents the formuation of the dimer impurity which reduces the activity of the compound of formula I in the treatment of cancer as a cell-growth inhibitor.
Description
PHARMACEUTICAL COMPOSITION COMPRISING AMIDE
DERIVATIVE INHIBITING THE GROWTH OF CANCER CELLS AND
NON-METALLIC SALT LUBRICANT
FIELD OF THE INVENTION
The present invention relates to a pharmaceutical composition comprising
an amide derivative or its pharmaceutically acceptable salt inhibiting the growth
of cancer cells and a non-metallic salt lubricant.
BACKGROUND OF THE INVENTION
The epidermal growth factor receptor (EGFR) is known to have four
receptor subtypes, i.e., EGFR/ErbB1, Her-2/ErbB2, Her-3/ErbB3, and Her-
4/ErbB4. They are abnormally overexpressed in most solid tumor cells. Also,
activation of the receptor by ligands leads to activation of the cellular signaling
pathway, which gives rise to growth, differentiation, angiogenesis, metastasis, and
resistance of tumor cells (A. Wells, Int. J. Biochem. Cell Biol., 1999, 31, 637-643).
Therefore, it is expected that blocking of the tumor cell signaling pathway
mediated by the epidermal growth factor receptor would produce antitumor effects.
Hence, there have been many research efforts for developing anticancer drugs
targeting the epidermal growth factor receptor.
Such anticancer drugs targeting the epidermal growth factor receptor are
categorized into two groups: monoclonal antibodies targeting an extracellular
domain and small molecule drugs targeting an intracellular tyrosine kinase. The
monoclonal antibodies have an advantage of a good pharmaceutical efficacy with
a less extent of side effects due to its selective binding on the epidermal growth
factor receptors. However, the monoclonal antibodies have drawbacks that they
are quite expensive and must be administered by injection. Meanwhile, the small
molecule drugs targeting a tyrosine kinase are relatively inexpensive and orally
administrable, and they also have a good pharmaceutical efficacy through reacting
with the receptor subtypes (e.g., EGFR, Her-2, Her-3 and Her-4) selectively or
simultaneously.
Examples of the small molecule drugs include selective inhibitors of EGFR
such as Iressa (Gefitinib, AstraZenaca) and Tarceva (Erlotinib, Roche), and dual
inhibitors simultaneously blocking EGFR and Her-2 such as Tykerb (Lapatinib,
GlaxoSmithKline). These drugs are currently being used for treating lung cancer
and advanced Her-2 positive breast cancer, respectively. Clinical trials therefor
are also being conducted to increase the efficacy against other solid tumors.
A recent study has reported that a second mutation--i.e., a threonine-to-
methionine substitution at the amino acid position 790 in adenosine triphosphate
(ATP)-binding sites to the EGFR tyrosin kinase domain--can reduce the binding
ability of the drug, which results in a drastic decrease in the drug response rate
(C.H. Gow, et al., PLoS Med., 2005, 2(9), e269). Thus, it is required to develop a
drug having enhanced inhibitory activities against EGFR resistant cancer cells.
Korean Patent Laid-open Publication No. 2008-0107294 discloses a
compound of formula (I), which selectively and effectively inhibits the growth of
cancer cells and the development of drug resistance induced by the EGFR and its
mutants without side effects. However, it has been found that the pharmaceutical
formulation comprising the compound of formula (I) as an active ingredient and
its pharmaceutically acceptable additives facilitates the formation of a compound
of formula (II) (hereinafter, referred to as the related compound IV) under certain
storage conditions, thereby reducing the amount of the compound of formula (I).
(I)
(II)
The purity of an active ingredient is an important factor for preparing a safe
and effective pharmaceutical composition because certain impurities contained in
a drug substance may produce side effects during treatment. Some of the
impurities can be removed during the preparation of the drug. But certain
materials produced by degradation of the drug due to the changes in such various
conditions as temperature, humidity and light may remain as impurities.
The present inventors have endeavored to study the factors that promote the
formation of the related compound IV during storage of a pharmaceutical
formulation comprising a compound of formula (I) and have found that
pharmaceutically acceptable additives, particularly metallic salts contained in
lubricants, cause expedition of the formation of the related compound IV. Hence,
the present inventors have developed a pharmaceutical composition having an
enhanced stability by employing a non-metallic salt lubricant, which is free of a
metallic salt component.
SUMMARY OF THE INVENTION
It is an object of the present invention to provide a pharmaceutical
composition with an improved stability, comprising an amide derivative or a
pharmaceutically acceptable salt thereof, which effectively inhibits the growth of
cancer cells.
In accordance with one aspect of the present invention, there is provided a
pharmaceutical composition comprising a compound of formula (I) or a
pharmaceutically acceptable salt thereof, and a non-metallic salt lubricant:
(I).
BRIEF DESCRIPTION OF THE DRAWINGS
The above and other objects and features of the present invention will
become apparent from the following description of the invention, when taken in
conjunction with the accompanying drawings, which respectively show:
Fig. 1: the stability test results showing the amount of the related
compound IV produced after heating the pharmaceutical compositions of
Examples 1 to 8 and Comparative Example 1 at 60℃;
Fig. 2: the stability test results showing the amount of the related
compound IV produced after heating the pharmaceutical compositions of
Comparative Examples 1 to 4 and Example 1 at 60℃;
Fig. 3: the accelerated stability test results showing the amount of the
related compound IV produced after exposure of the pharmaceutical compositions
of Examples 1 and 2 and Comparative Examples 1 and 3 under the accelerated
conditions (40℃ and 75% RH); and
Fig. 4: the accelerated stability test results in a HDPE bottle showing the
amount of the related compound IV produced after exposure of the pharmaceutical
compositions of Examples 1 and 2 and Comparative Examples 1 and 3 under
accelerated conditions (40℃ and 75% RH).
DETAILED DESCRIPTION OF THE INVENTION
The present invention provides a pharmaceutical composition comprising a
compound of formula (I) or a pharmaceutically acceptable salt thereof, and a non-
metallic salt lubricant:
(I).
Each ingredient of the inventive pharmaceutical composition is described
in detail as follows.
(a) Pharmaceutically active ingredient
The pharmaceutical composition according to the present invention
comprises a compound of formula (I) or a pharmaceutically acceptable salt thereof
as a pharmaceutically active ingredient.
The compound of formula (I) (hereinafter referred to as the code name
“HM781-36B”), as disclosed in Korea Patent Laid-open Publication No. 2008-
0107294, can selectively and effectively inhibit the growth of cancer cells and the
development of drug resistance induced by the EGFR and its mutants, while
causing no adverse side effects.
The pharmaceutically acceptable salt of the compound of formula (I)
includes, but is not limited to, an acid-addition salt of an inorganic or organic acid.
Examples of the inorganic acid-addition salt may include salts of hydrochloric
acid, sulfuric acid, disulfonic acid, nitric acid, phosphoric acid, perchloric acid, or
bromic acid; examples of the organic acid-addition salt may include salts of
formic acid, acetic acid, propionic acid, oxalic acid, succinic acid, benzoic acid,
citric acid, maleic acid, malonic acid, malic acid, tartaric acid, gluconic acid, lactic
acid, gestisic acid, fumaric acid, lactobionic acid, salicylic acid, phthalic acid,
embonic acid, aspartic acid, glutamic acid, camsylic acid, besylic acid, or
acetylsalicylic acid (aspirin). The pharmaceutically acceptable salt may also
include metal salts derived from alkali metals such as calcium, sodium,
magnesium, strontium, potassium, and the like.
In the present invention, the compound of formula (I) may be employed in
an amount ranging from 0.1 to 50% by weight, preferably 0.5 to 10% by weight,
based on the total weight of the composition. The compound may be contained
in the composition in an amount ranging from 0.1 mg to 100 mg, preferably 0.5 to
50 mg, per 1 dosage unit of the composition.
(b) Non-metallic salt lubricant
Lubricants are ingredients added to improve the compression process of
granules, and they are considered as a critical excipient, which plays important
roles in the manufacture of solid compressed compositions. Advantages of
employing lubricants include an improved flow of the powder or granular
materials, which allows them to be more readily filled in a die; a reduced friction
of the powder or granular materials as well as that between the powder or granular
materials and the punch or the die; and enhanced compressibility and
dischargeability of the tablets. Lubricants can be categorized as shown in Table
<Table 1>
Category Lubricant
Fatty acid calcium stearate, magnesium stearate, sodium stearyl
metal salts fumarate, zinc stearate
glyceryl behenate, glyceryl palmitostearate, glyceryl
Fatty acid esters monostearate, glyceryl trimyristate, glyceryl tristearate,
sucrose fatty acid ester
Fatty acids & alcohols palmitic acid, palmitoyl alcohol, stearic acid, stearyl alcohol
hydrogenated castor oil, mineral oil, hydrogenated vegetable
Oils
fumaric acid, polyethylene glycol (PEG 4000 & PEG 6000),
Others
polytetrafluoroethylene, talc
The pharmaceutical composition of the present invention comprising a
compound of formula (I) is characterized by the use of a non-metallic salt
lubricant in order to prevent the formation of the related compound IV, which may
otherwise be formed due to a metallic salt if it is contained in the composition.
The term “non-metallic salt lubricant” according to the present invention
refers to a lubricant that is free of metallic materials, e.g., such metallic salts as
calcium stearate, magnesium stearate, sodium stearayl fumarate, zinc stearate, and
the like. Examples of the non-metallic salt lubricant according to the present
invention may include fatty acid esters, fatty acids, fatty alcohols, oils, fumaric
acid, polyethylene glycols (PEGs), polytetrafluoroethylenes, starch, talc, and the
like. The enhanced storage stability of the inventive pharmaceutical composition
can be achieved by employing such non-metallic salt lubricants.
Specifically, examples of the non-metallic salt lubricant, which can be
used in the present invention, may include, but are not limited to, fatty acid esters
(e.g., glyceryl behenate, glyceryl palmitostearate, glyceryl monostearate, glyceryl
trimyristate, glyceryl tristearate, sucrose fatty acid ester, and the like); fatty acids
and fatty alcohols (e.g., palmitic acid, palmitoyl alcohol, stearic acid, stearyl
alcohol, and the like); oils (e.g., hydrogenated castor oil, mineral oil, hydrogenated
vegetable oil, and the like); fumaric acid; polyethylene glycol (e.g., PEG 4000 or
PEG 6000); polytetrafluoroethylene; starch; and talc. The non-metallic salt
lubricants may be used solely or as a mixture thereof.
Preferably, examplary non-metallic salt lubricants according to the present
invention may include sucrose fatty acid ester, hydrogenated vegetable oil, stearic
acid, glyceryl behenate, glyceryl palmitostearate, talc, starch, and PEG 6000, more
preferably sucrose fatty acid ester and hydrogenated vegetable oil.
In the present invention, the non-metallic salt lubricant may be employed
in an amount ranging from 0.1 to 100 parts by weight, preferably 0.1 to 50 parts
by weight, more preferably 0.25 to 10 parts by weight, based on 1 part by weight
of the compound of formula (I).
If the amount of the non-metallic salt lubricant employed is less than 0.1
parts by weight, a tablet formed would not be readily released from the die cast or
may stick to the die cast during the tablet formation. On the other hand, if the
amount is greater than 100 parts by weight, a tablet would suffer from such
problems as capping or delamination. Moreover, since lubricants are in general
hydrophobic, if they are employed in a large amount, they may cause such
unintended problems as a delayed disintegration and a low dissolution rate.
(c) Pharmaceutically acceptable additives
The pharmaceutical composition of the present invention may further
comprise pharmaceutically acceptable additives and can be formulated into a
variety of administration forms, preferably an oral administration form.
Representative examples of the formulation for oral administration may include
powder, tablet, pill, capsule, liquid, suspension, emulsion, syrup, and granule,
preferably tablet and capsule, but are not limited thereto.
In the present invention, the pharmaceutically acceptable additives may
include a diluent, a binder, a disintegrant, and the like.
Examples of the diluent may include microcrystalline cellulose, lactose,
mannitol, calcium phosphate, and the like; examples of the binder may include
povidone, hydroxypropyl cellulose (HPC), hydroxypropyl methylcellulose
(HPMC), polyvinyl alcohol (PVA), sodium carboxymethyl cellulose, and the like;
and examples of the disintegrant may include crospovidone, sodium
croscarmellose, sodium starch glycolate, and the like.
The diluent may be used in an amount ranging from 20 to 95% by weight,
the binder may be used in an amount ranging from 1 to 10% by weight, and the
disintegrant may be used in an amount ranging from 1 to 30% by weight, based on
the total weight of the composition.
The pharmaceutical composition of the present invention may be coated
with a coating substrate to prevent the composition from being in direct contact
with the hand or skin of a user.
The coating substrate that can be used in the present invention may
include a rapid release coating substrate, an enteric coating substrate, or a
sustained release coating substrate. The rapid release coating substrate may be
selected from the group consisting of hydroxypropyl cellulose, hydroxypropyl
methylcellulose, polyvinyl alcohol, polyvinyl alcohol-polyethylene glycol graft
polymer (Kollocoat IR , BASF), and a mixture thereof. The enteric coating
substrate may be selected from the group consisting of (meth)acrylate copolymer
(Eudragit , EVONIK), hydroxypropyl methylcellulose phthalate, cellulose acetate
phthalate, and a mixture thereof. The sustained release coating substrate may be
selected from the group consisting of cellulose acetate, ethyl cellulose, polyvinyl
acetate, and a mixture thereof.
The coating substrate may be coated on the surface of the composition in
an amount ranging from 1 to 50 parts by weight, preferably 1 to 30 parts by
weight, based on 100 parts by weight of the uncoated core.
The present invention also provides a method for preparing the
pharmaceutical composition comprising a compound of formula (I) or a
pharmaceutically acceptable salt thereof and a non-metallic salt lubricant.
A formulation of the pharmaceutical composition comprising the above-
mentioned ingredients can be prepared by the following method, which comprises
the steps of:
(1) mixing a compound of formula (I) or a pharmaceutically acceptable
salt thereof with such a pharmaceutically acceptable additive as a diluent and a
binder, and granulating the mixture to obtain granules;
(2) mixing the granules prepared in step (1) with such a pharmaceutically
acceptable additive as a diluent and a disintegrant, and adding a non-metallic salt
lubricant thereto to obtain mixed granules; and
(3) subjecting the mixed granules prepared in step (2) to a formulating
step.
In one embodiment of the present invention, the inventive pharmaceutical
composition can be prepared by admixing a compound of formula (I) and mannitol
in a solution of povidone in purified water, subjecting the prepared mixture to wet
granulation, and then drying the resulting granules. The prepared granules can be
formed into a tablet by mixing the prepared granules with mannitol and
Crospovidone, adding a non-metallic salt lubricant thereto, and then tableting the
mixed granules by a tablet machine.
The various steps related with the formulation of the pharmaceutical
composition of the present invention can be conducted according to conventional
techniques known in the art. Further, the method of the present invention may
further comprise the step of coating the formulation prepared in step (3) with the
above-mentioned coating substrates for convenient storage and ease of use.
The pharmaceutical composition of the present invention can effectively
inhibit the growth of cancer cells by comprising the compound of formula (I),
which selectively and effectively inhibits the growth of cancer cells and the
development of drug resistance induced by the EGFR and its mutants. Also, the
pharmaceutical composition of the present invention can inhibit the formation of
impurities (i.e., the related compounds IV) to less than 0.5% by weight under
extreme conditions (e.g., kept in an airtight HDPE container at 60℃ for 4 weeks),
and under accelerated conditions (e.g., kept in an airtight HDPE container at
40℃/75% RH for 6 months) by comprising the non-metallic salt lubricant.
Therefore, the pharmaceutical composition of the present invention can enhance
the efficacy and improve the stability of the compound of formula (I).
Therefore, the present invention provides a method to stabilize a
pharmaceutical composition comprising the compound of formula (I) or a
pharmaceutically acceptable salt thereof, comprising adding the non-metallic salt
lubricant to the pharmaceutical composition.
The following Examples are intended to further illustrate the present
invention without limiting its scope.
Examples
Examples 1 to 8: Preparation of pharmaceutical compositions comprising non-
metallic salt lubricants
Pharmaceutical compositions of Examples 1 to 3 were prepared by
employing a compound of formula (I) (hereinafter, referred to as “HM781-36B,”
Dongwoo Syntech Co., Ltd., Korea); mannitol (Roquette); Povidone (BASF);
Crospovidone (BASF); and sucrose fatty acid ester (Daiichi Kogyo Seiyaku, Japan),
hydrogenated vegetable oil (Lubritab , JRS Pharma), or stearic acid (Emery
Oleochemicals.), as a non-metallic salt lubricant, in accordance with the composition
and the amount (unit: mg) described in Table 2.
Specifically, HM781-36B and mannitol were mixed and the mixture was
subjected to a wet-granulation process by a conventional method with employing a
binder solution of Povidone dissolved in purified water. The wet granules thus
obtained were dried, mixed with mannitol and Crospovidone, and subsequently
added with a lubricant, which was previously sieved through a 30 mesh screen, to
prepare a final mixture. The final mixture thus prepared was formed into a tablet
having a hardness of about 5 to 10 kp by a tablet machine (Sejong, Korea) according
to a conventional method.
<Table 2>
Ex.1 Ex. 2 Ex. 3
HM781-36B 0.5 0.5 0.5
Mixture
Mannitol 50 50 50
Wet granule
Povidone 1.5 1.5 1.5
Binder
<Purified water> <10> <10> <10>
Mannitol 42 42 42
Mixture
Crospovidone 5 5 5
Sucrose fatty acid
2 - -
ester
Final mixture
Hydrogenated
vegetable oil
Stearic acid - - 1
Total weight 101 101 100
Pharmaceutical compositions of Examples 4 to 8 were prepared by the same
method as above by employing a compound of formula (I) (HM781-36B, Dongwoo
Syntech Co., Ltd., Korea); mannitol (Roquette); Povidone (BASF); Crospovidone
(BASF); and glyceryl behenate (Compritol 888 ATO , Gattefosse), glyceryl
palmitostearate (Compritol HD5 , Gatefosse), talc (Nippon Talc Corp., Japan),
starch (Roquette), or PEG 6000 (Sanyo Chemical, Japan), as a non-metallic salt
lubricant, in accordance with the composition and the amount (unit: mg) described in
Table 3.
<Table 3>
Ex. 4 Ex. 5 Ex. 6 Ex. 7 Ex. 8
HM781-36B 0.5 0.5 0.5 0.5 0.5
Mixture
Mannitol 50 50 50 50 50
granule Povidone 1.5 1.5 1.5 1.5 1.5
Binder
<Purified water> <10> <10> <10> <10> <10>
Mannitol 42 42 42 42 42
Mixture
Crospovidone 5 5 5 5 5
Glyceryl behenate 2 - - - -
Glyceryl
- -
palmitostearate
Final mixture
Talc - -
Starch - -
PEG 6000 3
Total weight 101 101 102 104 102
Pharmaceutical compositions of Examples 9 to 15 were prepared by the
same method as above by employing a compound of formula (I) (HM781-36B,
Dongwoo Syntech Co., Ltd., Korea); mannitol (Roquette); Povidone (BASF);
Crospovidone (BASF); and glyceryl monostearate (Capmul GMS-50), palmitoyl
alcohol (Landz International Company Ltd., China), stearyl alcohol (Lubrizol
Advanced Materials, U.S.), hydrogenated castor oil (BASF), mineral oil (Alfa Aesar,
U.S.), fumaric acid (Merck), or silicon dioxide (Grace Davison, U.S.), as a non-
metallic salt lubricant, in accordance with the composition and the amount (unit: mg)
described in Table 4.
<Table 4>
Ex. 9 Ex. 10 Ex. 11 Ex. 12 Ex. 13 Ex. 14 Ex. 15
HM781-36B 0.5 0.5 0.5 0.5 0.5 0.5 0.5
Mixture
Mannitol 50 50 50 50 50 50 50
granule Povidone 1.5 1.5 1.5 1.5 1.5 1.5 1.5
Binder
<Purified water> <10> <10> <10> <10> <10> <10> <10>
Mannitol 42 42 42 42 42 42 42
Mixture
Crospovidone 5 5 5 5 5 5 5
Glyceryl
- - - - - -
monostearate
Palmitoyl alcohol - - - -
Stearyl alcohol - - - -
Final mixture
Hydrogenated castor
- - - -
Mineral oil - - - -
Fumaric acid - - - -
Silicon dioxide - - - - - - 2
Total weight 104 104 104 104 104 104 101
Comparative Examples 1 to 4: Preparation of pharmaceutical compositions
comprising metallic salt lubricants
The procedures of the above Examples were repeated by employing the
composition and the amount (unit: mg) described in Table 5, to prepare
pharmaceutical compositions of Comparative Examples 1 to 4 comprising metallic
salt lubricants.
<Table 5>
Comp. Ex. 1 Comp. Ex. 2 Comp. Ex. 3 Comp. Ex. 4
HM781-36B 0.5 0.5 0.5 0.5
Mixture
Mannitol 50 50 50 50
granule Povidone 1.5 1.5 1.5 1.5
Binder
<Purified water> <10> <10> <10> <10>
Mannitol 42 42 42 42
Mixture
Crospovidone 5 5 5 5
Magnesium stearate 1 - - -
Calciumstearate -
Final mixture
Sodium stearyl
-
fumarate
Zinc stearate - - - 1
Total weight 100 100 100 100
Test Example: Measurement of the related compound formed
In order to evaluate the storage stability of the pharmaceutical compositions
prepared in Examples 1 to 8 and Comparative Examples 1 to 4, the pharmaceutical
compositions were each packaged with 1 g of silica gel in an HDPE bottle and stored
in a chamber (60℃). After 2 and 4 weeks, respectively, the related compound IV, a
major degradation product of HM781-36B, was extracted by 60% acetonitrile as a
solvent, and then HPLC analyses were performed. The results of Examples 1 to 8
are shown in Table 6 and Fig. 1, and those of Comparative Examples 1 to 4 are
shown in Table 7 and Fig. 2.
<Table 6>
Ex. 1 2 3 4 5 6 7 8
Initial 0.05 0.04 0.04 0.05 0.05 0.04 0.04 0.05
0.26 0.23 0.17 0.27 0.21 0.15 0.18 0.37
2 weeks, 60℃
4 weeks, 60℃ 0.34 0.35 0.31 0.38 0.36 0.26 0.29 0.45
<Table 7>
Comp. Ex. 1 2 3 4
Initial 0.04 0.04 0.04 0.04
2 weeks, 60℃ 1.52 0.98 1.60 1.09
4 weeks, 60℃ 2.46 2.25 3.41 1.98
In order to observe the changes of stability of the pharmaceutical
compositions prepared in accordance with Examples 1 and 2 and Comparative
Examples 1 and 3 against temperature and humidity, the pharmaceutical
compositions were exposed to 40℃ and 75% RH. After 1 and 2 weeks,
respectively, the related compound IV, a major degradation product of HM781-36B,
was extracted by 60% acetonitrile as a solvent, and then HPLC analyses were
performed. The results are shown in Table 8 and Fig. 3.
<Table 8>
Ex. 1 Ex. 2 Comp. Ex. 1 Comp. Ex. 3
Initial 0.05 0.04 0.04 0.04
0.12 0.10 0.73 0.32
1 week 40℃/75% RH
0.16 0.15 1.18 0.51
2 weeks 40℃/75% RH
In order to observe the changes of stability of the pharmaceutical
compositions prepared in accordance with Examples 1 and 2 and Comparative
Examples 1 and 3 against temperature and humidity under accelerated conditions,
the compositions were exposed to 40℃ and 75% RH in sealed HDPE containers for
1, 3 and 6 months. The related compound IV of each composition was extracted by
60% acetonitrile as a solvent, and then HPLC analyses were performed. The
results are shown in Table 9 and Fig. 4.
<Table 9>
Ex. 1 Ex. 2 Comp. Ex. 1 Comp. Ex. 3
Initial 0.05 0.04 0.04 0.04
1 month ACLTD 40 C 0.15 0.14 0.31 0.28
3 months ACLTD 40 C 0.17 0.15 0.41 0.32
6 months ACLTD 40 C 0.20 0.18 0.62 0.58
As shown in Tables 6 to 9 and Figs. 1 to 4, the formation of the related
compound IV was reduced by about 4 to 10 times or more in the pharmaceutical
compositions comprising any of the non-metallic salt lubricants compared with the
pharmaceutical compositions comprising the metallic salt lubricants. Thus, the
storage stability of the pharmaceutical compositions containing HM781-36B as an
active ingredient can significantly be enhanced by adding any of the non-metallic
salt lubricants to the pharmaceutical compositions.
According to the guidelines of the International Conference on
Harmonisation of Technical Requirements for Registration of Pharmaceuticals for
Human Use (ICH), the limits of unknown and known impurities are prescribed as
0.2% and 0.5%, respectively. The pharmaceutical compositions of Examples 1 and
2 according to the present invention showed satisfactory results of less than 0.5% at
40 ℃ in an accelerated stability test as described in the ICH guideline. In contrast,
the pharmaceutical compositions of Comparative Examples 1 and 3 comprising
conventional metallic salt lubricants exceeded the predetermined limits of the ICH
guideline.
While the invention has been described with respect to the above specific
embodiments, it should be recognized that various modifications and changes may
be made to the invention by those skilled in the art which also fall within the
scope of the invention as defined by the appended claims.
Claims (16)
1. A pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof and a non-metallic salt lubricant: (I).
2. The pharmaceutical composition of claim 1, wherein said non-metallic salt lubricant is selected from the group consisting of fatty acid esters, fatty acids, fatty alcohols, oils, fumaric acid, polyethylene glycols (PEGs), polytetrafluoroethylenes, talc, and a mixture thereof.
3. The pharmaceutical composition of claim 2, wherein said non-metallic salt lubricant is selected from the group consisting of glyceryl behenate, glyceryl palmitostearate, glyceryl monostearate, glyceryl trimyristate, glyceryl tristearate, sucrose fatty acid ester, palmitic acid, palmitoyl alcohol, stearic acid, stearyl alcohol, hydrogenated castor oil, mineral oil, hydrogenated vegetable oil, fumaric acid, PEG 4000, PEG 6000, polytetrafluoroethylene, starch, talc, and a mixture thereof.
4. The pharmaceutical composition of claim 3, wherein said non-metallic salt lubricant is sucrose fatty acid ester or hydrogenated vegetable oil.
5. The pharmaceutical composition of claim 1, wherein said compound of formula (I) is contained in an amount ranging from 0.1 mg to 100 mg per 1 dosage unit of the composition.
6. The pharmaceutical composition of claim 1, wherein said non-metallic salt lubricant is contained in an amount ranging from 0.1 to 100 parts by weight based on 1 part by weight of the compound of formula (I).
7. The pharmaceutical composition of claim 1, which further comprises a pharmaceutically acceptable additive selected from the group consisting of a diluent, a binder, a disintegrant, and a mixture thereof.
8. The pharmaceutical composition of claim 7, wherein said diluent is contained in an amount ranging from 20% to 95% by weight based on the total weight of the composition.
9. The pharmaceutical composition of claim 7, wherein said binder is contained in an amount ranging from 1% to 10% by weight based on the total weight of the composition.
10. The pharmaceutical composition of claim 7, wherein said disintegrant is contained in an amount ranging from 1% to 30% by weight based on the total weight of the composition.
11. The pharmaceutical composition of claim 1, which is coated with a coating substrate selected from the group consisting of a rapid release coating substrate, an enteric coating substrate, and a sustained release coating substrate.
12. The pharmaceutical composition of claim 11, wherein said coating substrate is selected from the group consisting of hydroxypropyl cellulose, hydroxylpropyl methylcellulose, polyvinyl alcohol, polyvinyl alcohol- polyethylene glycol graft copolymer, (meth)acrylic acid copolymer, phthalic acid hydroxypropyl methylcellulose, phthalic acid cellulose acetate, cellulose acetate, ethyl cellulose, polyvinyl acetate, and a mixture thereof.
13. The pharmaceutical composition of claim 1, which comprises a compound of formula (II) less than 0.5% by weight under extreme conditions kept in an airtight HDPE container at 60℃ for 4 weeks, or under accelerated conditions kept in an airtight HDPE container at 40℃ and 75% RH for 6 months: (II)
14. A method for preparing a formulation of the pharmaceutical composition of claim 1, which comprises the steps of: (1) mixing a compound of formula (I) or a pharmaceutically acceptable salt thereof with a pharmaceutically acceptable additive, and granulating the mixture to obtain granules; (2) mixing the granules prepared in step (1) with a pharmaceutically acceptable additive, and adding a non-metallic salt lubricant thereto to obtain mixed granules; and (3) subjecting the mixed granules prepared in step (2) to a formulating step. (I).
15. The method of claim 14, which further comprises the step of coating the formulation prepared in step (3) with a coating substrate selected from the group consisting of a rapid release coating substrate, an enteric coating substrate, and a sustained release coating substrate.
16. A method for stabilizing a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, comprising adding a non-metallic salt lubricant to the pharmaceutical composition: (I). FIG. 4
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2011-0054685 | 2011-06-07 | ||
KR1020110054685A KR101317809B1 (en) | 2011-06-07 | 2011-06-07 | Pharmaceutical composition comprising amide derivative inhibiting the growth of cancer cell and non-metalic salt lubricant |
PCT/KR2012/003970 WO2012169733A1 (en) | 2011-06-07 | 2012-05-18 | Pharmaceutical composition comprising amide derivative inhibiting the growth of cancer cells and non-metallic salt lubricant |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ619606A NZ619606A (en) | 2015-07-31 |
NZ619606B2 true NZ619606B2 (en) | 2015-11-03 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9931406B2 (en) | Pharmaceutical composition comprising amide derivative inhibiting the growth of cancer cells and non-metallic salt lubricant | |
KR101290925B1 (en) | Coated tablet formulation and method | |
TWI424995B (en) | Pharmaceutical composition comprising amide derivative or pharmaceutically acceptable salt thereof | |
RU2651460C2 (en) | COMBINED COMPOSITION CONTAINING METFORMIN OF SUSTAINED RELEASE AND INHIBITOR HMG-CoA-REDUCTASE OF IMMEDIATE RELEASE | |
NZ619606B2 (en) | Pharmaceutical composition comprising amide derivative inhibiting the growth of cancer cells and non-metallic salt lubricant | |
US20220378790A1 (en) | Pharmaceutical preparation comprising an amide derivative inhibiting the growth of cancer cell and a pharmaceutical product containing the same | |
KR20090012168A (en) | Solid formulation containing ibuprofen and tranexamic acid | |
TW202128170A (en) | A pharmaceutical preparation comprising an amide derivative inhibiting the growth of cancer cell and a pharmaceutical product containing the same |